Opinion|Videos|July 17, 2024
AGAVE-201 Investigating Axatilimab In Recurrent of Refractory cGVHD
Author(s)Hannah Choe, MD
Dr. Hannah Choe reviews data from the AGAVE-201 trial investigating the CSF-1R inhibitor axatilimab, including efficacy, safety, and clinical implications of these data for patients with recurrent or refractory chronic GVHD.
Advertisement
Advertisement
Related to this article
The anti-CD19/CD20 CAR T-cell therapy will be studied in the phase 2 ABZT-121 trial after progression on commercial CAR T-cell therapy.
Read a refresh of hematologic cancer FDA news from October 2026, including the approval of a noncovalent BTK inhibitor in untreated CLL/SLL.
Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
Alembic's generic venetoclax, therapeutically equivalent to Venclexta, received final FDA approval for CLL/SLL and newly diagnosed AML.
Advertisement
Advertisement
Trending on OncLive
1
Dr Johnson on Immune Activation With Indoximod-Based Chemo-Immunotherapy in Recurrent Ependymoma
2
Tovorafenib Sustains Treatment-Free Intervals in R/R BRAF-Altered Pediatric Low-Grade Glioma
3
Dr Miller on Whole Genome Sequencing of CSF ctDNA in High-Grade Glioma
4
Patient Preferences Steer Decisions as Options Multiply Across EGFR-Mutated NSCLC
5